Brokerages expect Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Rating) to report sales of $9.59 million for the current fiscal quarter, Zacks reports. Four analysts have made estimates for Nurix Therapeutics’ earnings, with estimates ranging from $8.00 million to $11.54 million. Nurix Therapeutics posted sales of $7.09 million during the same quarter last year, which indicates […]
Related Keywords
Thomson Reuter , Robertw Baird , Zacks Investment Research , Blackrock Inc , Nasdaq , Pte Ltd , Needham Company , Ep Wealth Advisors , Wells Fargo Company , Nurix Therapeutics Inc , Nurix Therapeutics , Get Rating , Nurix Therapeutic , Investment Research , Casitasb Lineage , Nasdaq Nrix , Winrix , Medical , Ratings , Consensus ,
comparemela.com © 2020. All Rights Reserved.